Answer
Yes, life-threatening pancreatitis was reported in 1% of patients in the Enrylaze (recombinant crisantaspase) clinical trial.
Sources for this answer
- Enrylaze 10 mg/0.5 ml Solution for injection/infusionJazz Pharmaceuticals UK Limited · emc · SmPC §4.8 Undesirable effects · Version 2Document updated
Sources checked